Shares of GUSHENGTANG (02273.HK) surged 5.15% in intraday trading on Friday, following the release of its impressive 2025 interim results and shareholder-friendly initiatives. The traditional Chinese medicine healthcare provider announced strong financial performance, a significant dividend increase, and a substantial share repurchase program, driving investor enthusiasm.

GUSHENGTANG reported robust growth in its half-year results, with revenue rising 9.5% year-over-year to RMB 1.49 billion and net profit soaring 41.6% to RMB 152 million. The company's profitability outpaced revenue growth, demonstrating improved operational efficiency and a sustainable business model. Additionally, GUSHENGTANG's free cash flow showed remarkable growth, surging 466% year-over-year to RMB 210 million, highlighting the company's strong cash-generating capabilities.

Further boosting investor confidence, GUSHENGTANG declared an interim dividend of HK$0.35 per share, a substantial increase from HK$0.13 in the same period last year. The company also announced plans to repurchase shares worth up to HK$300 million, reflecting management's confidence in the company's long-term prospects. These shareholder-friendly moves, combined with the strong financial performance and positive outlook for its traditional Chinese medicine business, contributed to the stock's significant intraday gain.